Consensus recommendations from the American Acne & Rosacea Society on the Management of Rosacea, Part 3: A status report on systemic therapies

James Q. Del Rosso, Diane Thiboutot, Richard Gallo, Guy Webster, Emil Tanghetti, Lawrence F. Eichenfield, Linda Stein-Gold, Diane Berson, Andrea Zaenglein

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The third article in this 5-part series reviews systemic therapies used to treat cutaneous rosacea based on consensus recommendations from the American Acne & Rosacea Society (AARS) on the management of the common presentations of cutaneous rosacea. The consensus recommendations are based on current understanding of research that describes pathophysiologic mechanisms that appear to be operative in rosacea, correlation of these underlying pathophysiologic mechanisms with specific clinical manifestations of rosacea, and outcomes from clinical trials that evaluate therapies for rosacea both as monotherapy and in combination with other agents. Systemic agents used for treatment of rosacea have been administered as oral formulations (ie, tablets, capsules). The only oral agent for rosacea approved by the US Food and Drug Administration (FDA) is a modified-release doxycycline 40-mg capsule. Other non-FDA-approved oral agents also are discussed including other tetracyclines, macrolides, metronidazole, and isotretinoin.

Original languageEnglish (US)
Pages (from-to)18-28
Number of pages11
JournalCutis
Volume93
Issue number1
StatePublished - Jan 1 2014

Fingerprint

Rosacea
Acne Vulgaris
Therapeutics
Capsules
Tetracyclines
Isotretinoin
Skin
Doxycycline
Macrolides
Metronidazole
United States Food and Drug Administration
Tablets
Oral Administration
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Dermatology

Cite this

Del Rosso, James Q. ; Thiboutot, Diane ; Gallo, Richard ; Webster, Guy ; Tanghetti, Emil ; Eichenfield, Lawrence F. ; Stein-Gold, Linda ; Berson, Diane ; Zaenglein, Andrea. / Consensus recommendations from the American Acne & Rosacea Society on the Management of Rosacea, Part 3 : A status report on systemic therapies. In: Cutis. 2014 ; Vol. 93, No. 1. pp. 18-28.
@article{51d6760aeece4fd08e488ae3b94c53f6,
title = "Consensus recommendations from the American Acne & Rosacea Society on the Management of Rosacea, Part 3: A status report on systemic therapies",
abstract = "The third article in this 5-part series reviews systemic therapies used to treat cutaneous rosacea based on consensus recommendations from the American Acne & Rosacea Society (AARS) on the management of the common presentations of cutaneous rosacea. The consensus recommendations are based on current understanding of research that describes pathophysiologic mechanisms that appear to be operative in rosacea, correlation of these underlying pathophysiologic mechanisms with specific clinical manifestations of rosacea, and outcomes from clinical trials that evaluate therapies for rosacea both as monotherapy and in combination with other agents. Systemic agents used for treatment of rosacea have been administered as oral formulations (ie, tablets, capsules). The only oral agent for rosacea approved by the US Food and Drug Administration (FDA) is a modified-release doxycycline 40-mg capsule. Other non-FDA-approved oral agents also are discussed including other tetracyclines, macrolides, metronidazole, and isotretinoin.",
author = "{Del Rosso}, {James Q.} and Diane Thiboutot and Richard Gallo and Guy Webster and Emil Tanghetti and Eichenfield, {Lawrence F.} and Linda Stein-Gold and Diane Berson and Andrea Zaenglein",
year = "2014",
month = "1",
day = "1",
language = "English (US)",
volume = "93",
pages = "18--28",
journal = "Cutis",
issn = "0011-4162",
publisher = "Quadrant Healthcom Inc.",
number = "1",

}

Del Rosso, JQ, Thiboutot, D, Gallo, R, Webster, G, Tanghetti, E, Eichenfield, LF, Stein-Gold, L, Berson, D & Zaenglein, A 2014, 'Consensus recommendations from the American Acne & Rosacea Society on the Management of Rosacea, Part 3: A status report on systemic therapies', Cutis, vol. 93, no. 1, pp. 18-28.

Consensus recommendations from the American Acne & Rosacea Society on the Management of Rosacea, Part 3 : A status report on systemic therapies. / Del Rosso, James Q.; Thiboutot, Diane; Gallo, Richard; Webster, Guy; Tanghetti, Emil; Eichenfield, Lawrence F.; Stein-Gold, Linda; Berson, Diane; Zaenglein, Andrea.

In: Cutis, Vol. 93, No. 1, 01.01.2014, p. 18-28.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Consensus recommendations from the American Acne & Rosacea Society on the Management of Rosacea, Part 3

T2 - A status report on systemic therapies

AU - Del Rosso, James Q.

AU - Thiboutot, Diane

AU - Gallo, Richard

AU - Webster, Guy

AU - Tanghetti, Emil

AU - Eichenfield, Lawrence F.

AU - Stein-Gold, Linda

AU - Berson, Diane

AU - Zaenglein, Andrea

PY - 2014/1/1

Y1 - 2014/1/1

N2 - The third article in this 5-part series reviews systemic therapies used to treat cutaneous rosacea based on consensus recommendations from the American Acne & Rosacea Society (AARS) on the management of the common presentations of cutaneous rosacea. The consensus recommendations are based on current understanding of research that describes pathophysiologic mechanisms that appear to be operative in rosacea, correlation of these underlying pathophysiologic mechanisms with specific clinical manifestations of rosacea, and outcomes from clinical trials that evaluate therapies for rosacea both as monotherapy and in combination with other agents. Systemic agents used for treatment of rosacea have been administered as oral formulations (ie, tablets, capsules). The only oral agent for rosacea approved by the US Food and Drug Administration (FDA) is a modified-release doxycycline 40-mg capsule. Other non-FDA-approved oral agents also are discussed including other tetracyclines, macrolides, metronidazole, and isotretinoin.

AB - The third article in this 5-part series reviews systemic therapies used to treat cutaneous rosacea based on consensus recommendations from the American Acne & Rosacea Society (AARS) on the management of the common presentations of cutaneous rosacea. The consensus recommendations are based on current understanding of research that describes pathophysiologic mechanisms that appear to be operative in rosacea, correlation of these underlying pathophysiologic mechanisms with specific clinical manifestations of rosacea, and outcomes from clinical trials that evaluate therapies for rosacea both as monotherapy and in combination with other agents. Systemic agents used for treatment of rosacea have been administered as oral formulations (ie, tablets, capsules). The only oral agent for rosacea approved by the US Food and Drug Administration (FDA) is a modified-release doxycycline 40-mg capsule. Other non-FDA-approved oral agents also are discussed including other tetracyclines, macrolides, metronidazole, and isotretinoin.

UR - http://www.scopus.com/inward/record.url?scp=84893175012&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893175012&partnerID=8YFLogxK

M3 - Article

C2 - 24505581

AN - SCOPUS:84893175012

VL - 93

SP - 18

EP - 28

JO - Cutis

JF - Cutis

SN - 0011-4162

IS - 1

ER -